N/A
N=22
A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria
Secondary Hyperoxaluria · Nephrolithiasis · Hyperoxaluria · Kidney Stones
Bottom Line
View on ClinicalTrials.gov: NCT03095885 ↗Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Mar 2020
Primary outcome: Primary: Percent of Oxalate Absorption Normalized by Baseline Urinary Oxalate Excretion Over a 24 Hour Test Period — 2.84 percentage of oxalate absorption
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Test Meal (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Allena Pharmaceuticals
- Primary completion
- Jan 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent of Oxalate Absorption Normalized by Baseline Urinary Oxalate Excretion Over a 24 Hour Test Period |
2.84 | — |
| SECONDARY Percent of Oxalate Absorption By Test Interval |
2.11; 3.55; 10.83 | — |
| SECONDARY Percent Change From Baseline for Urinary Oxalate to Creatinine Ratio by Test Interval |
68.17; 84.73; 45.39; 47.14 | — |
Summary
Identify individuals with greater absorption of oxalate based on increase in urinary oxalate excretion in response to a controlled oxalate-rich test meal.
Eligibility Criteria
Inclusion Criteria
- Males or non-pregnant and non-lactating females
- History of hyperoxaluria secondary to a known underlying enteric disease (e.g., Crohn's disease, bariatric surgery, and others) or without a known underlying cause (idiopathic), and kidney stones.
- Urinary oxalate ≥ 40 mg of oxalate/24 hr at screening.
- If taking drugs for the prevention of stone disease, including pyridoxine, thiazides (chlorthalidone, hydrochlorothiazide, and indapamide), citrate supplements, and allopurinol, there must have been no changes in these medications for at least one month prior to screening and no changes are anticipated for the duration of the study.
- Able to understand and provide written informed consent.
Exclusion Criteria
- Under or over-collection on screening 24-hour urine collection (mg creatinine/kg body weight outside of gender-specific range).
- Estimated glomerular filtration rate (eGFR) <40 mL/minute/1.73 m^2 or acute renal failure.
- Primary hyperoxaluria.
- Allergy, intolerance, or any other factors limiting ability to consume the study foods or adhere to the study meal schedule.
- Positive pregnancy test during Screening.
- Clinically significant findings (including acute renal colic), an ongoing clinically significant illness requiring changes in management, or any planned medical/surgical procedure during the study.
- Malignancy undergoing active therapy; patients in remission on chronic suppressive or maintenance therapies are not excluded.
- Investigational compound within 30 days prior to screening.
- Investigator determined that the subject would not be able to adhere or to complete the study procedures , or could not discontinue Vitamin C supplements, calcium supplements, or other medications that could interfere with oxalate absorption and/or excretion.
Data sourced from ClinicalTrials.gov (NCT03095885). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.